201857-39-8

Basic information

• Product Name: 4-AMINO-3-BROMO-5-CHLOROBENZONITRILE
• Synonyms: 4-AMINO-3-BROMO-5-CHLOROBENZONITRILE;3-Chloro-4-amino-5-bromobenzonitrile
• CAS NO: 201857-39-8
• Molecular Formula: C₇H₄BrClN₂
• Molecular Weight: 231.48
• Mol File: 201857-39-8.mol

Chemical Properties

• Melting Point: 109-111
• Boiling Point: 292.3 °C at 760 mmHg
• Flash Point: 130.6 °C
• Appearance: /
• Density: 1.81 g/cm³
• Vapor Pressure: 0.00185mmHg at 25°C
• Refractive Index: 1.665
• CAS DataBase Reference: 4-AMINO-3-BROMO-5-CHLOROBENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-3-BROMO-5-CHLOROBENZONITRILE(201857-39-8)
• EPA Substance Registry System: 4-AMINO-3-BROMO-5-CHLOROBENZONITRILE(201857-39-8)

Safety Data

• Hazardous Substances Data: 201857-39-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINO-3-BROMO-5-CHLOROBENZONITRILE is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-AMINO-3-BROMO-5-CHLOROBENZONITRILE is employed as a precursor in the production of pesticides and other agrochemicals, contributing to the development of effective solutions for crop protection and management.
Used in Dye and Pigment Production:
4-AMINO-3-BROMO-5-CHLOROBENZONITRILE is utilized as an intermediate in the manufacturing process of dyes and pigments, enabling the creation of a wide range of colorants for various applications, including textiles, plastics, and printing inks.

InChI:InChI=1/C7H4BrClN2/c8-5-1-4(3-10)2-6(9)7(5)11/h1-2H,11H2

Upstream product

• 21803-75-8 4-amino-3-chlorobenzonitrile 

Relevant articles and documents

Aminoacetamide acyl guanidines as beta-secretase inhibitors

There is provided a series of substituted acyl guanidines of Formula (Ik) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R2, R3, R4, R5, R25, R26 and R27 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.